Pacific Biosciences of California, which is developing a system that performs real-time DNA sequencing, raised $200 million by offering 12,500,000 shares at $16, the midpoint of the $15-$17 range. The news comes the same day that another next-generation DNA sequencer, Complete Genomics (GNOM), announced terms for a $78 million IPO. Pacific Biosciences of California plans to list on the NASDAQ under the symbol PACB. J.P. Morgan and Morgan Stanley were the bookrunners on the deal.
